Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody (original) (raw)

A new type of anti-ganglioside antibodies present in neurological patients

R. Saizar

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2006

View PDFchevron_right

A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells

Nelson Santiago Vispo

Molecular Immunology, 2002

View PDFchevron_right

Antitumor and cytotoxic properties of a humanized antibody specific for the GM3(Neu5Gc) ganglioside

Circe Mesa

Immunobiology, 2015

View PDFchevron_right

A common mechanism and a new categorization for anti-ganglioside antibody-mediated neuropathies

Antonino Uncini

Experimental Neurology, 2012

View PDFchevron_right

Specific killing of human melanoma cells by 125I-labeled 9.2.27 monoclonal antibody

George Morstyn

Cancer Research, 1985

View PDFchevron_right

Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody

Mats Ökvist

Molecular Immunology, 2009

View PDFchevron_right

A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity

Jean-Marie MUSSINI

PLoS ONE, 2011

View PDFchevron_right

Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells

Circe Mesa

Scientific Reports, 2019

View PDFchevron_right

Monoclonal antibodies for cancer: a focus on mechanisms of action

Hardik Gandhi

Journal of Integrated Health Sciences, 2013

View PDFchevron_right

Structural basis of GD2 ganglioside and mimetic peptide recognition by 14G2a antibody

Michal Kolinski

Molecular & Cellular Proteomics, 2015

View PDFchevron_right

A Mouse IgG1Monoclonal Antibody Specific forN-Glycolyl GM3 Ganglioside Recognized Breast and Melanoma Tumors

Circe Mesa

Hybridoma, 2000

View PDFchevron_right

Monoclonal and bispecific antibodies as novel therapeutics

Sherif Louis

Archivum Immunologiae et Therapiae Experimentalis, 2006

View PDFchevron_right

Molecular Mechanisms of Antibody Somatic Hypermutation

Javier M Di Noia

Annual Review of Biochemistry, 2007

View PDFchevron_right

Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells

Circe Mesa

Cancer Immunology, Immunotherapy, 2005

View PDFchevron_right

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

Inger Sandlie

Nature Reviews Drug Discovery, 2003

View PDFchevron_right

An anti-DNA antibody prefers damaged dsDNA over native

Rustem Litvinov

Journal of Biomolecular Structure and Dynamics, 2016

View PDFchevron_right

Monoclonal antibodies: Pharmacological relevance

Prem Khosla

Indian Journal of Pharmacology, 2007

View PDFchevron_right

Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastoma

Ningyan Zhang

PLOS ONE, 2022

View PDFchevron_right

Aspects of cancer immunotherapy

Bruce Loveland

Immunology and Cell Biology, 2003

View PDFchevron_right

Cell surface gangliosides are involved in the control of human glioma cell invasion in vitro

Abderrahim MERZAK

Neuroscience Letters, 1994

View PDFchevron_right

Genetic modulation of tumor antigen presentation

Eric von Hofe

Trends in Biotechnology, 2000

View PDFchevron_right

Gangliosides, Ab1 and Ab2 antibodies

Marco Bestagno

Molecular Immunology, 2007

View PDFchevron_right

Gangliosides, Ab1 and Ab2 antibodiesIII. The idiotype of anti-ganglioside mAb P3 is immunogenic in a T cell-dependent manner

Marco Bestagno, Oscar Burrone

Molecular Immunology, 2007

View PDFchevron_right

Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP)

Circe Mesa

Vaccine, 1999

View PDFchevron_right

Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells

A. Corti

mAbs, 2013

View PDFchevron_right

Guanidine-reactive agent phenylglyoxal induces DNA damage and cancer cell death

Santiago Mateos

Pharmacological Reports, 2012

View PDFchevron_right

Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies

Danilo Gomes

Journal of Immunological Methods, 2008

View PDFchevron_right

Immunotherapeutic Strategies for Malignant Glioma

Robert Fenstermaker

Cancer Control, 2004

View PDFchevron_right

Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity

Lourdes Roque

Molecular Cancer Therapeutics, 2008

View PDFchevron_right

Simple method for selecting catalytic monoclonal antibodies that exhibit turnover and specificity

Rina Arad-Yellin

Biochemistry, 1990

View PDFchevron_right

Mutation Analysis of the C1 Inhibitor Gene

Arkadius Kocot

34th Hemophilia Symposium

View PDFchevron_right

Apoptosis Induced via Gamma Delta T Cell Antigen Receptor “Blocking” Antibodies: A Cautionary Tale

Indrani Dutta

Frontiers in Immunology, 2017

View PDFchevron_right

Protective Antifungal Yeast Killer Toxin-Like Antibodies

R. Frazzi

Current Molecular Medicine, 2005

View PDFchevron_right

Characterization of anti-ganglioside antibodies present in normal human plasma

gustavo nores

Journal of neuroimmunology, 1994

View PDFchevron_right

Engineering antibodies for clinical applications

NEEL KAMAL

Trends in Biotechnology, 2007

View PDFchevron_right